FDA gives Rhythm the green light for set­melan­otide, a drug aimed at re­duc­ing obe­si­ty in cer­tain ge­net­ic dis­or­ders

A lit­tle over a year af­ter com­plet­ing suc­cess­ful piv­otal tri­als, Rhythm Phar­ma­ceu­ti­cals $RYTM has its first drug ap­proval on its hands.

The Boston-based biotech an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER